Workflow
益方生物拟用不超10亿元闲置募集资金进行现金管理

Core Viewpoint - The company Yifang Biotechnology (Shanghai) Co., Ltd. has approved the use of up to RMB 1 billion of temporarily idle raised funds for cash management to enhance fund utilization efficiency and increase returns for shareholders [1][2][4]. Fundraising Basic Situation - The company was approved to publicly issue 115 million shares at a price of RMB 18.12 per share, raising a total of RMB 2,083.8 million, with a net amount of approximately RMB 1,982.15 million after deducting related issuance costs [2]. Cash Management Details - The purpose of cash management is to improve the efficiency of raised fund usage while ensuring project construction and fund safety. The company plans to invest in high-security, liquid, and principal-protected financial products or deposit products, with a maximum investment period of 12 months [2]. - The decision is valid for 12 months from the date of board approval, and the funds can be used in a rolling manner [2]. Review Procedures and Risk Control - The company has established a robust approval and execution process for cash management, including measures such as using a special account, board authorization for operational decisions, and supervision by independent directors and internal audit departments [3]. - Despite choosing low-risk products, market fluctuations may still impact investments, and the company will ensure that funds are returned to the special account or rolled over upon maturity [3]. Impact on the Company and Sponsor Opinions - The cash management will not affect the company's daily cash flow, project construction progress, or main business development, while also improving fund utilization efficiency and overall performance [4]. - The sponsor institution has confirmed that the necessary decision-making procedures have been followed, and the action complies with relevant laws and regulations, with no objections raised regarding the matter [4].